Tetrahydrocurcumin for Health & Longevity - Quick Reference Sheet

Tetrahydrocurcumin for Health & Longevity

Created on 10/21/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Tetrahydrocurcumin, a colorless form of curcumin sold as a dietary supplement, is marketed as a more stable, better-absorbed source of curcumin's proposed anti-inflammatory and cell-protective effects. Lifespan and organ-protection effects come only from animal studies. Human evidence is thin and mixed, much of it from the main manufacturer; Europe's daily limit is below trial doses, and rare turmeric-linked liver injury remains a concern: a plausible but largely untested longevity candidate. (Full Review)

Protocol

Regulatory dose ceiling
140 mg/day
Tetrahydrocurcuminoids for adults; EU-authorized maximum in food supplements
Manufacturer-proposed and trial doses
200–300 mg/day
Trials used 100 mg twice daily and 200 mg/day, both above the EU ceiling; Sabinsa proposed 300 mg/day
Single vs split dose
Two doses
Common practice, as in the oral-health trial
Time to effect
Canker sore and gingivitis symptom relief
21 days
Less mouth-ulcer pain and gum inflammation by day 21; no control group
Vitiligo repigmentation (topical, with phototherapy)
8–12 weeks
Direction favored cream plus ultraviolet B light, without statistical significance
Longevity
Years
If real; never measured in people

Benefits

Contraindications
  • Pregnant or breastfeeding women, and anyone under adult age
  • People with prior turmeric- or curcumin-associated liver injury, or a history of liver problems without medical supervision
  • People with bleeding disorders or scheduled surgery (theoretical)
  • People with gallstones or bile-duct obstruction (theoretical)
  • People receiving chemotherapy without oncologist approval (theoretical)
Key Interactions
  • Anticoagulants and antiplatelet drugs (clot-preventing medicines: warfarin, clopidogrel): Caution (theoretical)
  • Drugs cleared by CYP2C9 (warfarin, phenytoin): Monitor (theoretical)
  • Drugs cleared by CYP3A4 or ABCB1 (tacrolimus, cyclosporine): Caution (theoretical)
  • Glucose-lowering drugs (insulin, metformin): Monitor (theoretical)
  • Over-the-counter NSAIDs (nonsteroidal anti-inflammatory drugs: ibuprofen, naproxen) and aspirin: Caution (theoretical)
  • Other curcumin or turmeric supplements: Avoid on the same day
  • Piperine (black pepper extract): Caution (theoretical)
  • Additive antiplatelet supplements (fish oil, ginkgo): Caution (theoretical)
  • Additive glucose-lowering supplements (berberine, chromium): Monitor (theoretical)
  • Surgery and dental procedures: Caution (theoretical)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Drug-induced liver injury; Minor gastrointestinal and general complaints; Allergic contact dermatitis; Gallbladder contraction
  • Speculative: Increased bleeding tendency; Altered levels of other medications; Reproductive and developmental effects; Low blood sugar with diabetes medication

Monitoring

Marker Target Why
ALT 7–56 U/L Safety check: rise stops use
AST 10–40 U/L Safety check: rise stops use
Total bilirubin 0.1–1.2 mg/dL Safety check: rise stops use
INR (warfarin users only) Prescriber's individual range Safety check: rise changes use
Fasting glucose (users of glucose-lowering drugs) 70–99 mg/dL Safety check: low values change use
hs-CRP Change from own baseline Expected to change; proposed anti-inflammatory effect, unproven in humans

Cadence: Baseline before starting; liver enzymes at 4–6 weeks and 3 months, then every 6–12 months; INR within 1–2 weeks of starting or stopping (warfarin users); more frequent home glucose checks in the first month (diabetes medication); immediate testing at jaundice, dark urine or abdominal pain

Qualitative Assessment

  • Oral comfort, including gum bleeding and mouth-ulcer frequency
  • Joint comfort and morning stiffness
  • Digestive tolerance (bloating, stool changes)
  • Mood and energy
  • Early signs of liver injury: fatigue, itching, dark urine, yellow eyes
  • Unusual bruising or bleeding